Dr Rick Thompson joined Findacure in 2015, after completing his PhD in Evolutionary Biology at the University of Cambridge. He has recently moved to the position of CEO, after working as Head of Research. He is responsible for the running and development of the charity, as well as their scientific projects. These aim to develop a socially financed drug repurposing programme – Findacure’s rare disease drug repurposing social impact bond (RDDR SIB). Rick has designed and completed a proof of concept study to demonstrate the feasibility of the RDDR SIB to the NHS, investors, industry, and patient groups. Rick works to encourage industry engagement with rare disease patient groups, promoting an open and collaborative approach to rare disease research.